key: cord-0784278-sqdu65eq authors: Hirotsu, Y.; Maejima, M.; Shibusawa, M.; Natori, Y.; Nagakubo, Y.; Hosaka, K.; Sueki, H.; Mochizuki, H.; Tsutsui, T.; Kakizaki, Y.; Miyashita, Y.; Omata, M. title: Classification of Omicron BA.1, BA.1.1 and BA.2 sublineages by TaqMan assay consistent with whole genome analysis data date: 2022-04-05 journal: nan DOI: 10.1101/2022.04.03.22273268 sha: 9c378d4e5986733e13304cefc2b46f5e1b4bf7d7 doc_id: 784278 cord_uid: sqdu65eq Objective Recently, the Omicron strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread and replaced the previously dominant Delta strain. Several Omicron sublineages (BA.1, BA.1.1 and BA.2) have been identified, with in vitro and preclinical reports showing that the pathogenicity and therapeutic efficacy differs between BA.1 and BA.2. We sought to develop a TaqMan assay to identify these subvariants. Methods A TaqMan assay was constructed for rapid identification and genotyping of Omicron sublineages. We analyzed three characteristic mutations of the spike gene, {Delta}69-70, G339D and Q493R, by TaqMan assay. The accuracy of the TaqMan assay was examined by comparing its results with the results of whole genome sequencing (WGS) analysis. Results A total of 169 SARS-CoV-2 positive samples were analyzed by WGS and TaqMan assay. The 127 samples determined as BA.1/BA.1.1 by WGS were all positive for {Delta}69-70, G339D and Q493R by TaqMan assay. Forty-two samples determined as BA.2 by WGS were negative for {Delta}69-70 but positive for G339D and Q493R by TaqMan. The concordance rate between WGS and the TaqMan assay was 100% (169/169). Conclusion TaqMan assays targeting characteristic mutations are useful for identification and discrimination of Omicron sublineages. Running title: TaqMan assay discriminates Omicron sublineages 28 29 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Introduction 54 The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-55 2) has become a threat to human life. However, since its outbreak, scientific knowledge has 56 accumulated on the transmission and pathogenicity of this virus. Additionally, the 57 development of vaccines and antiviral treatments has contributed to preventing infection and 58 reduced the risk of severe illness and mortality. 59 SARS-CoV-2 is an RNA virus with a genome size of approximately 30 kb [1] . SARS-60 CoV-2 mutates at a rate of approximately two mutations per month [2] , and is prone to 61 mutations most frequently occurring in the spike and orf1ab genes [3] . These mutations can 62 affect transmissibility of the virus and efficacy of antiviral drugs and vaccines. To control the 63 emergence of new strains, it is important to continuously monitor viral evolution through 64 genomic epidemiological analysis [4] . 65 Recently, a new strain designated B. In this study, we present a TaqMan assay to discriminate between BA.1/BA.1.1 and 87 BA.2. This method is feasible for any laboratory equipped to perform quantitative real-time 88 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. Tokyo, Japan) were used for this study [19, 20] . 100 101 We subjected 171 samples collected from coronavirus disease 2019 (COVID-19) 103 patients to whole genome analysis (Table S1 ). WGS analysis was performed as previously 104 described [21] [22] [23] . In brief, SARS-CoV-2 genomic RNA was reverse transcribed into cDNA 105 and amplified by using the Ion AmpliSeq SARS-CoV-2 Insight Research Assay (Thermo 106 Fisher Scientific, Waltham MA) on the Ion Torrent Genexus System. Sequencing reads and 107 quality were processed using Genexus software with SARS-CoV-2 plugins. The 108 sequencing reads were mapped and aligned using the torrent mapping alignment program. 109 Assembly was performed with the Iterative Refinement Meta-Assembler [24] . Accession IDs are noted in Table S1 . 115 116 We used the pre-designed TaqMan SARS-CoV-2 Mutation Panel for detecting 118 SARS-CoV-2 spike Δ69-70, G339D and Q493R (Thermo Fisher Scientific). The TaqMan 119 probe detected both wild-type and variant sequences of SARS-CoV-2, with the TaqMan minor 120 groove binder probe for the wild-type allele labelled with VIC dye and the variant allele with 121 FAM dye fluorescence. TaqPath 1-Step RT-qPCR Master Mix CG was used as master mix 122 and the qPCR was performed on the Step-One Plus Real Time PCR System (Thermo Fisher 123 Scientific). 124 125 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.03.22273268 doi: medRxiv preprint The To distinguish BA.1/BA.1.1 from BA.2, we constructed a TaqMan assay system to 144 analyze the spike protein mutations that characterize the Omicron sublineages. Thus, we 145 To examine whether the TaqMan assay could accurately distinguish Omicron 156 sublineages, we compared WGS data and TaqMan assay results using 169 SARS-CoV-2 157 positive samples (Table 1) were negative for Δ69-70 and positive for G339D and Q493R (Table 1 ). The TaqMan assay 161 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.03.22273268 doi: medRxiv preprint data were consistent with WGS data, demonstrating 100% (169/169) agreement. Therefore, 162 the TaqMan assay represents a useful technique for distinguishing Omicron sublineages. in Figure 3B ). In conclusion, the TaqMan assay used in this study specifically detected 175 characteristic mutations related to Omicron sublineages in clinical samples. 176 177 In this study, we present data regarding the use of a TaqMan assay to distinguish 179 between Omicron strains and their sublineages. WGS analysis is the most standard method 180 to determine these sublineages. However, WGS analysis of all specimens is restricted by 181 limited resources and is difficult to apply under conditions of rapid spread of infection. In this 182 regard, we have established a TaqMan assay that more conveniently and rapidly identifies 183 Omicron strains and distinguishes the sublineages. BA.1/BA. It is also possible to target other mutations as reported by other groups [31, 32] . Analysis of 197 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. It should also be noted that if mutations occur at the TaqMan probe or primer locations, the 212 PCR amplification efficiency will be reduced and the signal will be attenuated, which may 213 make interpretation difficult ( Figure 3B) . 214 Our study showed that the TaqMan assay can be used to specifically detect Omicron 215 viruses and classify subvariants. By applying this method to SARS-CoV-2-positive 216 specimens, it is possible to analyze multiple specimens rapidly. Although accumulated data 217 are still needed [8, 11, 14, 34] , BA.1 and BA.2 show different susceptibilities to antibody and 218 antiviral therapy. Rapid classification of Omicron sublineages may be clinically critical in 219 providing appropriate treatment to patients with COVID-19. 220 221 The sequences of SARS-CoV-2 genomes are available on GISAID 223 (www.gisaid.org). We have provided the accession numbers in the Supplementary 224 Information. Source data are provided with this paper. 225 226 We thank all medical and ancillary hospital staff for their support. We thank Gillian 228 Campbell, PhD, from Edanz (https://www.jp.edanz.com/ac) for editing a draft of this 229 manuscript. 230 231 The authors have no conflicts of interest. 233 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Antibody evasion properties of SARS-CoV-2 Omicron sublineages Omicron BA.1 and BA.2 are antigenically 274 distinct SARS-CoV-2 variants Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants Efficacy of Antiviral Agents 280 against the SARS-CoV-2 Omicron Subvariant BA.2 Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant Development of Genetic Diagnostic Methods for Novel Coronavirus 287 2019 (nCoV-2019) in Japan . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 The percentages of spike mutations Δ69-70, G339D and Q493R in each VOC analyzed in 380 this study are shown. The pink circles indicate the presence of mutations. The frequency of 381 mutation data was referenced from the website outbreak.info [29] . 382 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022